 MAP Kinase Kinase Kinases
"MAP Kinase Kinase Kinases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Mitogen-activated protein kinase kinase kinases (MAPKKKs) are serine-threonine protein kinases that initiate protein kinase signaling cascades. They phosphorylate MITOGEN-ACTIVATED PROTEIN KINASE KINASES; (MAPKKs) which in turn phosphorylate MITOGEN-ACTIVATED PROTEIN KINASES; (MAPKs).
| Descriptor ID |
D020930
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.559 D12.644.360.400 D12.776.476.400
|
| Concept/Terms |
MAP Kinase Kinase Kinases- MAP Kinase Kinase Kinases
- MAP Kinase Kinase Kinase
- MAPKKKs
- Mitogen-Activated Protein Kinase Kinase Kinases
- Mitogen Activated Protein Kinase Kinase Kinases
- Kinases, MAP Kinase Kinase
- MAP3 Kinases
- Kinases, MAP3
MAPK-ERK Kinase Kinases- MAPK-ERK Kinase Kinases
- Kinase Kinases, MAPK-ERK
- Kinases, MAPK-ERK Kinase
- MAPK ERK Kinase Kinases
- MEKKs
- MEK Kinases
- Kinases, MEK
|
Below are MeSH descriptors whose meaning is more general than "MAP Kinase Kinase Kinases".
Below are MeSH descriptors whose meaning is more specific than "MAP Kinase Kinase Kinases".
This graph shows the total number of publications written about "MAP Kinase Kinase Kinases" by people in UAMS Profiles by year, and whether "MAP Kinase Kinase Kinases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2020 | 0 | 1 | 1 | | 2019 | 3 | 0 | 3 | | 2016 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2010 | 0 | 2 | 2 | | 2009 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2007 | 1 | 1 | 2 | | 2005 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "MAP Kinase Kinase Kinases" by people in Profiles over the past ten years.
-
Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020 10; 26(10):1564-1568.
-
Zhou J, An C, Jin X, Hu Z, Safirstein RL, Wang Y. TAK1 deficiency attenuates cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol. 2020 01 01; 318(1):F209-F215.
-
Guibao CD, Petrinjak K, Moldoveanu T. Uncovering human mixed lineage kinase domain-like activation in necroptosis. Future Med Chem. 2019 11; 11(21):2831-2844.
-
Westin SN, Sill MW, Coleman RL, Waggoner S, Moore KN, Mathews CA, Martin LP, Modesitt SC, Lee S, Ju Z, Mills GB, Schilder RJ, Fracasso PM, Birrer MJ, Aghajanian C. Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study. Gynecol Oncol. 2019 12; 155(3):420-428.
-
Zhao Y, Feresin RG, Falcon-Perez JM, Salazar G. Differential Targeting of SLC30A10/ZnT10 Heterodimers to Endolysosomal Compartments Modulates EGF-Induced MEK/ERK1/2 Activity. Traffic. 2016 Mar; 17(3):267-88.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|